|Preferred IUPAC name
3D model (JSmol)
|Molar mass||659.81 g/mol|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
what is ?)(
Lasinavir (INN, previously known as BMS-234475 and CGP-61755) is an experimental peptidomimetic protease inhibitor researched by Novartis and Bristol-Myers Squibb as a treatment for HIV infection. It was originally discovered by Novartis at Basel (Switzerland). Its investigation was terminated after Phase I on October 09, 2002.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names (Rec. INN): List 38" (PDF). WHO Drug Information. World Health Organization. 11 (3): 170. 1997. Retrieved 25 November 2015.
- B2 US patent 7348345 B2, James Patrick Dunn, Steven Swallow, Zachary Kevin Sweeney, "Nonnucleoside reverse transcriptase inhibitors", issued 2008-08-02
- "Drug Profile: Lasinavir". AdisInsight. Adis International Ltd, part of Springer Science+Business Media. Retrieved 25 November 2015.